ISRCTN59616541已完成不适用
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults
Merck and Co., Inc. (USA)0 个研究点目标入组 500 人开始时间: 2005年1月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current information as of 13/08/09:
- •1. Male or female patients aged 18 or over
- •2. Patient has a diagnosis of intra-abdominal infection requiring surgery as evidenced by fever, elevated while blood cell count and abdominal pain
- •Initial information at time of registration:
- •Adult patients with intra-abdominal infections requiring surgery
排除标准
- •Added 13/08/09:
- •1. Patient has another infection, other than abdominal
- •2. Female patient is pregnant or planning to become pregnant
研究者
相似试验
已完成
不适用
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults-A499 Bacterial infection, unspecifiedBacterial infection, unspecifiedA499PER-063-01MERCK SHARP & DOHME PERU S.R.L.,
Unknown
不适用
A clinical study to check the effect medicine to control the Diarrhea in children.CTRI/2019/06/019838Dr Vijay Yewale
进行中（未招募）
1 期
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical ConditionsCTIS2023-504034-22-00F. Hoffmann-La Roche AG397
进行中（未招募）
1 期
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutatioChronic Lymphocytic Leukemia (CLL)MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-504036-17-00F. Hoffmann-La Roche AG166
招募中
2 期
Study of the effect of Siddha Treatment in addition to standard therapy in COVID-19 patientsCTRI/2020/06/025625Eminentlabs Business Solutions Pvt Ltd